Berkshire Hathaway Inc. New
Stocks
Johnson & Johnson
Stocks
Berkshire Hathaway Inc. New vs Johnson & Johnson: A Performance-Driven Stock Comparison
Last updated: June 5, 2026
Summary
Berkshire Hathaway Inc. leads in market capitalization and revenue, highlighting its dominance in financial services, while Johnson & Johnson outperforms in dividend yield and profit margin, reflecting its strength in healthcare. Both stocks exhibit distinct performance profiles suited to different investor priorities.
Key Differences at a Glance
| Aspect | Berkshire Hathaway Inc. New | Johnson & Johnson | Winner |
|---|---|---|---|
| Market Capitalization | $1,032,334,934,016 | $549,254,660,096 | Berkshire Hathaway Inc. New |
| Revenue | $375.39 billion | $96.36 billion | Berkshire Hathaway Inc. New |
| Earnings Per Share (EPS) | 33.61 | 8.64 | Berkshire Hathaway Inc. New |
| Dividend Yield | None | 2.4% | Johnson & Johnson |
| Profit Margin | 19.3% | 21.8% | Johnson & Johnson |
Market Capitalization: Berkshire Hathaway's market cap is nearly double that of Johnson & Johnson, indicating a larger market valuation and investor confidence in its diversified financial portfolio.
Revenue: Berkshire Hathaway reports significantly higher revenue, reflecting its extensive operations across multiple sectors, especially within insurance and diversified investments.
Earnings Per Share (EPS): Berkshire Hathaway’s EPS is nearly four times higher than Johnson & Johnson’s, indicating stronger profitability per share on an earnings basis.
Dividend Yield: Johnson & Johnson offers a robust dividend yield of 2.4%, providing steady income for investors, whereas Berkshire Hathaway does not currently pay dividends, favoring capital appreciation.
Profit Margin: Johnson & Johnson’s profit margin surpasses Berkshire Hathaway’s by approximately 2.5 percentage points, emphasizing its efficiency in healthcare manufacturing and sales.
Detailed Analysis
Berkshire Hathaway Inc. stands out with its impressive market capitalization of over $1 trillion, making it one of the largest publicly traded companies in the United States. Its revenue of $375.39 billion underscores its diversified business model, primarily within insurance, which contributes to its robust financial performance. With an EPS of 33.61 and a PE ratio of approximately 14.24, Berkshire Hathaway demonstrates strong earnings relative to its stock price, appealing to investors seeking growth and value. Its beta of 0.622 indicates moderate volatility, suggesting it is less sensitive to market swings compared to more volatile stocks.
In contrast, Johnson & Johnson operates predominantly in the healthcare sector, with a revenue of nearly $96.36 billion and a market cap of around $549 billion. Its EPS of 8.64, combined with a higher PE ratio of approximately 26.41, indicates that investors are willing to pay more for its earnings, reflecting confidence in its pharmaceutical and consumer health segments. Johnson & Johnson’s profit margin of 21.8% surpasses Berkshire Hathaway’s, highlighting operational efficiency within its core business lines. Additionally, its dividend yield of 2.4% makes it an attractive option for income-focused investors.
Performance-wise, Berkshire Hathaway excels in growth metrics, with significantly higher revenue and market cap, making it ideal for investors prioritizing capital appreciation in the financial services domain. Conversely, Johnson & Johnson’s higher profit margin and dividend yield cater to investors seeking stable income and consistent profitability in the healthcare industry. The lower beta of 0.263 for Johnson & Johnson suggests it is less volatile, offering a safer investment during turbulent market periods. Both stocks exhibit strong performance indicators but excel in different performance-focused areas—Berkshire Hathaway in scale and earnings, Johnson & Johnson in profitability and income stability.
Verdict
Berkshire Hathaway Inc. is the clear winner in terms of overall market performance, revenue, and earnings, making it the better choice for growth-oriented investors seeking exposure to diversified financial services. However, Johnson & Johnson outperforms in dividend yield, profit margin, and stability, making it more suitable for income-focused and risk-averse investors. The optimal choice depends on whether investors prioritize growth or income, but in pure performance metrics, Berkshire Hathaway leads due to its larger scale and profitability.
Who Should Choose What
Choose Berkshire Hathaway Inc. New if...
Best for investors seeking high growth potential, exposure to diversified financial markets, and larger market capitalization; suitable for long-term capital appreciation.
Choose Johnson & Johnson if...
Best for investors prioritizing steady income through dividends, stable profit margins, and lower volatility; ideal for conservative income investors and those focused on healthcare stability.
Learn More
Related Comparisons
Centene Corporation vs Berkshire Hathaway Inc.: Practical Daily-Use Stock Comparison
Johnson & Johnson vs CrowdStrike Holdings, Inc.: Practical Daily-Use Investment Comparison
Berkshire Hathaway Inc. New vs KeyCorp: A Beginner's Guide to Investing in Top U.S. Financial Stocks
Johnson & Johnson vs Regency Centers Corporation: Performance Comparison for Investors
Berkshire Hathaway Inc. New vs American Water Works Company, I: A Comprehensive Expert Comparison